{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-004946","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-01-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.118444+00:00","generated_at":"2026-06-06T21:28:21.211460+00:00","sec_items":["1.01","2.03","3.02","3.03","5.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Allarity enters $440K convertible note with 3i, LP; Series A conversion price cut to $0.4476","bullets":["Issued $440K principal senior convertible note to 3i, LP at $400K purchase price (10% OID), due Jan 18, 2025, 8% interest.","Conversion price set at $0.4476 per share; Purchaser limited to 4.99% beneficial ownership cap.","Second closing of $440K note at same terms may be required by company; potential additional $600K notes.","Series A Preferred Stock conversion price amended from $1.00 to $0.4476 via Fifth Amendment.","Proceeds used for accounts payable and working capital; negative covenants restrict further debt over $250K."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-004946","json":"https://secwatch.observer/filing/0001213900-24-004946.json","markdown":"https://secwatch.observer/filing/0001213900-24-004946.md","text":"https://secwatch.observer/filing/0001213900-24-004946.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024004946/0001213900-24-004946-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024004946/ea191856-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T21:28:21.211460+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"95c5e888bbdb93915532d095f8874452038335ba","claim":"Allarity Therapeutics, Inc. incurred convertible notes of $440,000 with 3i, LP at 8% per annum maturing January 18, 2025.","evidence_excerpt":"we issued and sold to the Purchaser a senior convertible promissory note in an aggregate principal amount of $440,000 (the “Principal Amount”) due on January 18, 2025","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024004946/0001213900-24-004946-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$440,000"},{"label":"Counterparty","value":"3i, LP"},{"label":"Rate","value":"8% per annum"},{"label":"Maturity","value":"January 18, 2025"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"5a9812dd514bcd4c2b19d85b0750ad181a3514c3","claim":"Allarity Therapeutics, Inc. entered into Securities Purchase Agreement with 3i, LP valued at $440,000 (effective 2024-01-18).","evidence_excerpt":"On January 18, 2024 (the “First Closing Date”), Allarity Therapeutics, Inc., a Delaware corporation (“we,” “our,” or the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with 3i, LP, a Delaware limited partnership (the “Purchaser”), pursuant to which we issued and sold to the Purchaser a senior convertible promissory note in an aggregate principal amount of $440,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024004946/0001213900-24-004946-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"3i, LP"},{"label":"Value","value":"$440,000"},{"label":"Effective","value":"2024-01-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}